Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.

Biotechnology

Education

Lucy Therapeutics

Lucy Therapeutics' headquarters in Cambridge, MA, United States

This department provides strategic direction and oversight for the organization's governance and executive functions.

Executive Leadership

The Scientific Advisors team at Lucy Therapeutics plays a critical role in guiding the company's research and development efforts by providing expert insights and strategic recommendations on mitochondrial-targeted drug discovery. They leverage their extensive knowledge in neurobiology and pharmacology to assess the viability of potential drug candidates and optimize dosing regimens. Additionally, they collaborate with other teams to ensure that the scientific foundation of LucyTx's approach is robust and aligned with the latest advancements in the field, particularly for conditions like Rett Syndrome and Parkinson’s disease.

Scientific Advisors

The Research and Development Team at Lucy Therapeutics is dedicated to advancing the company's innovative drug discovery efforts by conducting rigorous experimental studies to validate targets associated with early disease pathogenesis. This team leverages their expertise in mitochondrial function to explore and develop novel therapeutic strategies for CNS diseases such as Rett Syndrome and Parkinson’s, ensuring a focus on disease modification rather than symptom management. Through collaboration and cross-functional research, they aim to establish proof of concept and optimize dosing regimens to enhance neuroprotection and potential clinical outcomes.

Research and Development Team

The Leadership Team at Lucy Therapeutics drives the strategic vision and operational execution of the company’s mission to revolutionize drug discovery through early intervention in disease pathogenesis. Composed of key executives including the CEO and CFO, the team oversees business development, financial strategy, and the advancement of innovative therapies targeting mitochondrial function in neurodegenerative diseases, ensuring alignment with the company's unique approach to disease modification and proof of concept initiatives.

��

People (2)

Jobs (0)

Other teams

Scientific Advisors

Research and Development Team

Leadership Team

��������

People (2)

Jobs (0)

Other teams

Scientific Advisors

Research and Development Team

Leadership Team

��